Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New UK Rare Disease Framework Seeks Better Patient Access & More International Collaboration

Executive Summary

England, Scotland, Wales and Northern Ireland will publish their respective action plans to deliver the aims of the UK’s new framework for rare diseases.

You may also be interested in...



New UK Rare Disease Framework Seeks To Reduce ‘Diagnostic Odyssey’ For Patients

England, Scotland, Wales and Northern Ireland will publish their respective action plans to deliver the aims of the UK’s new framework for rare diseases.

UK Conservatives Promise ‘Innovative Medicines Fund’ If Re-Elected

More money to pay for innovative new medicines, more cash and support for the life sciences sector, and Brexit by 31 January 2020 are among promises made in the Conservative Party’s election platform. 

Kite Strikes CAR-T Access & Discount Deal For Tecartus In England

Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel